<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03993262</url>
  </required_header>
  <id_info>
    <org_study_id>ZKSJ0120</org_study_id>
    <secondary_id>2019-001423-12</secondary_id>
    <secondary_id>DRKS00017497</secondary_id>
    <nct_id>NCT03993262</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis</brief_title>
  <acronym>Generate-Boost</acronym>
  <official_title>A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jena University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jena University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autoimmune Encephalitis is a disorder of the central nervous system caused by bodily
      substances, called antibodies. Antibodies normally help the body to prevent infections.
      However, in this disorder, the antibodies turn against the body itself and especially against
      cells in the brain and disturb the normal brain function. They are therefore called
      autoantibodies.

      There is no specific therapy for patients with autoimmune encephalitis so far. At the moment,
      the symptoms are treated with approved medications such as cortisone and immunotherapies also
      used in oncology. These therapies are unspecified and aim to reduce the number of
      autoantibodies and to contain the autoimmune process. In this trial we aim to test a new
      therapy option: in this therapy the body cells producing autoantibodies will be specifically
      targeted by a substance called bortezomib.

      The trial addresses patients with severe autoimmune encephalitis. The aim of the trial is to
      evaluate the efficacy and safety of bortezomib in patients with severe autoimmune
      encephalitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autoimmune encephalitis is characterized by autoantibodies against neuronal surface antigens
      like the NMDA (N-methyl-D-aspartate) receptor or LGI1 (Leucin-rich glioma inactivated protein
      1). So far, no specific therapy exists for this disease. Actual treatment includes
      combination therapies aiming for a reduction of pathogenic antibodies and containing the
      autoimmune process. In first line, patients are treated with plasmapheresis and cortisone. In
      second line, Rituximab and/or cyclophosphamide are administered. The response to these
      treatments are, however, often delayed and insufficient.

      Therefore, we need a specific therapy aiming at the antibody-producing plasma cells.

      Bortezomib is a proteasome inhibitor which interferes with NF-kB (nuclear factor kB) and the
      ubiquitin proteasome signaling pathway. Bortezomib acts preferably on cells with high protein
      synthesis - like plasma cells - and induces cell death in these cells. Bortezomib is used
      since more than a decade in chemotherapy of the multiple myeloma. Additionally, it is
      reported for systemic autoimmune diseases like lupus erythematodes that bortezomib leads to a
      depletion of plasma cells and therefore reduces the number of pathogenic antibodies and
      improves clinical outcome. The therapeutic potential of bortezomib for NMDAR encephalitis is
      described in a first case series with 5 patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 13, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1 randomization will be done centrally and stratified by site. Block randomization of variable block sizes will be used.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The study drug will be provided blinded by the local pharmacy.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>modified Rankin-Score (mRS)</measure>
    <time_frame>17 weeks after first administration of the study drug</time_frame>
    <description>modified Rankin-Score from 0 = no symptoms to 6 = death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>modified Rankin-Score (mRS)</measure>
    <time_frame>3, 6, 9 and 13 weeks after first administration of the study drug; GCS Score also 17 weeks after first administration of the study drug</time_frame>
    <description>modified Rankin-Score from 0 = no symptoms to 6 = death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of in-hospital stay / length of ICU stay</measure>
    <time_frame>until 17 weeks after first administration of the study drug</time_frame>
    <description>Number of days in hospital or on ICU for each patient from first administration of the study drug until 17 weeks after first administration of the study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune response</measure>
    <time_frame>at study start and 17 weeks after first administration of the study drug</time_frame>
    <description>Antibody titer (in serum and liquor) and cellular immune response (FACS analysis of liquor)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neurocognitive function assessed by Montreal Cognitive Assessment</measure>
    <time_frame>at study start and 17 weeks after first administration of the study medication</time_frame>
    <description>total score of the Montreal Cognitive Assessment (MoCA) (0 to max. 30 points = best possible result)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neurocognitive function assessed by Mini-Mental Status Test</measure>
    <time_frame>at study start and 17 weeks after first administration of the study medication</time_frame>
    <description>total score of the Mini-Mental Status Test (MMST) (0 to max 30 points = best possible result)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neurocognitive function assessed by Rey Auditory Verbal Learning Test</measure>
    <time_frame>at study start and 17 weeks after first administration of the study medication</time_frame>
    <description>total score of the Rey Auditory Verbal Learning Test (RAVLT) (memory performance assessed by 3 word lists which are read to the patient and should be recalled and repeated by the patient; different proceeding for the 3 word lists)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neurocognitive function assessed by Neuropsychiatric Inventory Questionnaire</measure>
    <time_frame>at study start and 17 weeks after first administration of the study medication</time_frame>
    <description>total score of the Neuropsychiatric Inventory Questionnaire (NPI) (0 = best score to max 36 (patient) or 60 (caregiver)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety of Bortezomib regarding polyneuropathy, increase of liver enzymes and secondary infections</measure>
    <time_frame>until 17 weeks after first administration of the study drug</time_frame>
    <description>number of polyneuropathy cases, number of increased liver enzymes, number of secondary infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety of Bortezomib regarding polyneuropathy</measure>
    <time_frame>until 17 weeks after first administration of the study drug</time_frame>
    <description>number of polyneuropathy cases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety of Bortezomib regarding increase of liver enzymes</measure>
    <time_frame>until 17 weeks after first administration of the study drug</time_frame>
    <description>number of increased liver enzyme values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary infections due to Bortezomib</measure>
    <time_frame>until 17 weeks after first administration of the study drug</time_frame>
    <description>number of secondary infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematotoxicity events due to Bortezomib</measure>
    <time_frame>until 17 weeks after first administration of the study drug</time_frame>
    <description>number of hematotoxicity events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal toxicity due to Bortezomib</measure>
    <time_frame>until 17 weeks after first administration of the study drug</time_frame>
    <description>number of gastrointestinal toxicity events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total Glasgow Coma Scale (GCS)</measure>
    <time_frame>3, 6, 9, 13 and 17 weeks after first administration of the study drug</time_frame>
    <description>GCS from 3 to 15 points (sum of 3 subscores eye response (1 to 4 points), motor response (1 to 6 points), verbal response (1 to 5 points); highest score = best score; 1= worst score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Destruction marker UCH-L1 (Ubiquitin carboxy-terminal hydrolase L1) in serum and liquor</measure>
    <time_frame>at baseline visit and 17 weeks after first administration of the study drug</time_frame>
    <description>Analysis of destruction marker UCH-L1 in serum and liquor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Destruction marker Neurofilament light chain (in serum and liquor)</measure>
    <time_frame>at baseline visit and 17 weeks after first administration of the study drug</time_frame>
    <description>Analysis of destruction marker Neurofilament light chain in serum and liquor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Destruction markers GFAP (glial fibrillary acidic protein) in serum and liquor</measure>
    <time_frame>at baseline visit and 17 weeks after first administration of the study drug</time_frame>
    <description>Analysis of destruction marker GFAP in serum and liquor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Destruction marker TAU proteins in serum and liquor</measure>
    <time_frame>at baseline visit and 17 weeks after first administration of the study drug</time_frame>
    <description>Analysis of destruction marker TAU in serum and liquor</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Autoimmune Encephalitis</condition>
  <arm_group>
    <arm_group_label>Interventional</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 to 3 cycles Bortezomib with 1,3mg/m2 body surface s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 to 3 cycles placebo (NaCl solution) s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>1 to 3 cycles Bortezomib with 1,3mg/m2 body surface s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)</description>
    <arm_group_label>Interventional</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 to 3 cycles placebo (NaCl solution) s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>isotonic NaCl solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically diagnosed severe autoimmune encephalitis (defined as mRS ≥ 3) with
             autoantibodies to neuronal surface proteins in cerebrospinal fluid and / or serum

          -  Pretreatment with rituximab

          -  Age ≥18 years

          -  signed informed consent

          -  Women of childbearing potential (up to 2 years after menopause): negative pregnancy
             test

        Exclusion Criteria:

          -  pregnancy/breast-feeding

          -  acute infiltrative pulmonary and pericardial disease

          -  malignant tumor under current chemotherapy

          -  Simultaneous participation in another intervention study

          -  Previous participation in this study

          -  Known hypersensitivity to an ingredient of the investigational product

          -  Continued therapy with glucocorticoids / rituximab during the study duration (last
             dose must be administered before the first dose of the investigational product)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Geis, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Jena</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Geis, Prof.</last_name>
    <phone>+49 (0) 3641</phone>
    <phone_ext>9323413</phone_ext>
    <email>Christian.Geis@med.uni-jena.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jonathan Wickel, Dr.</last_name>
    <phone>+49 (0) 3641</phone>
    <phone_ext>9323561</phone_ext>
    <email>Jonathan.Wickel@med.uni-jena.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ludwig-Maximilians-Universität München, Klinikum Großhadern</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tania Kümpfel, Prof.</last_name>
      <phone>+49894400</phone>
      <phone_ext>74435</phone_ext>
      <email>tania.kuempfel@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Joachim Havla, Dr.</last_name>
      <phone>+49894400</phone>
      <phone_ext>74435</phone_ext>
      <email>joachim.havla@med.uni-muenchen.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <state>Bayern</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudia Sommer, Prof.</last_name>
      <phone>+49931201</phone>
      <phone_ext>23763</phone_ext>
      <email>sommer_c@ukw.de</email>
    </contact>
    <contact_backup>
      <last_name>Kathrin Doppler, PD Dr.</last_name>
      <phone>+49931201</phone>
      <phone_ext>23787</phone_ext>
      <email>doppler_K@ukw.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kurt-Wolfram Suehs, PD Dr.</last_name>
      <phone>+49511532</phone>
      <phone_ext>2495</phone_ext>
      <email>Suehs.Kurt-Wolfram@mh-hannover.de</email>
    </contact>
    <contact_backup>
      <last_name>Martin Stangel, Prof.</last_name>
      <phone>+49511532</phone>
      <phone_ext>6676</phone_ext>
      <email>Stangel.Martin@mh-hannover.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum der RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simone Tauber, Prof. Dr.</last_name>
      <phone>+49 241 80 89</phone>
      <phone_ext>827</phone_ext>
      <email>stauber@ukaachen.de</email>
    </contact>
    <contact_backup>
      <last_name>Arno Reich, Dr.</last_name>
      <phone>+49 241 8080</phone>
      <phone_ext>720</phone_ext>
      <email>areich@ukaachen.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin, Klinik für Neurologie mit Experimenteller Neurologie</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harald Pruess, PD Dr.</last_name>
      <phone>+49 30 450560</phone>
      <phone_ext>560</phone_ext>
      <email>harald.pruess@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Peter Koertvelyessy, Dr.</last_name>
      <phone>+49 30 450560</phone>
      <phone_ext>164</phone_ext>
      <email>p.koertvelyessy@dzne.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ruhr-Universität Bochum, St. Josef Hospital, Klinik für Neurologie</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilya Ayzenberg, PD Dr.</last_name>
      <phone>+49 234 509</phone>
      <phone_ext>6423</phone_ext>
      <email>Ilya.Ayzenberg@ruhr-uni-bochum.de</email>
    </contact>
    <contact_backup>
      <last_name>Ruth Schneider, Dr.</last_name>
      <phone>+49 234 509</phone>
      <phone_ext>6433</phone_ext>
      <email>ruth.schneider@rub.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen Georg-August-Universität, Klinik für Neurologie</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dirk Fitzner, Dr.</last_name>
      <phone>+49 551 39</phone>
      <phone_ext>65593</phone_ext>
      <email>d.fitzner@med.uni-goettingen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena, Sektion Translationale Neuroimmunologie, Klinik für Neurologie</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Geis, Prof.</last_name>
      <phone>+49-3641</phone>
      <phone_ext>-9323413</phone_ext>
      <email>Christian.Geis@med.uni-jena.de</email>
    </contact>
    <contact_backup>
      <last_name>Jonathan Wickel, Dr.</last_name>
      <phone>+49 3641</phone>
      <phone_ext>9323561</phone_ext>
      <email>Jonathan.Wickel@med.uni-jena.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinik für Neurologie UKSH, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Leypoldt, PD Dr.</last_name>
      <phone>+49 431 500</phone>
      <phone_ext>16209</phone_ext>
      <email>frank.leypoldt@uksh.de</email>
    </contact>
    <contact_backup>
      <last_name>Klarissa Stuerner, Dr.</last_name>
      <phone>+49 431 500</phone>
      <phone_ext>23816</phone_ext>
      <email>klarissa.stuerner@uksh.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig, Klinik und Poliklinik für Neurologie</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Florian Then Berg, Prof. Dr.</last_name>
      <phone>+49 341972</phone>
      <phone_ext>4320</phone_ext>
      <email>Florian.ThenBergh@medizin.uni-leipzig.de</email>
    </contact>
    <contact_backup>
      <last_name>Lars-Malte Teusser, Dr.</last_name>
      <phone>+49 341972</phone>
      <phone_ext>4320</phone_ext>
      <email>lars-malte.teusser@medizin.uni-leipzig.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz, Klinik und Poliklinik für Neurologie</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Bittner, Prof.</last_name>
      <phone>+49 6131 17</phone>
      <phone_ext>2805</phone_ext>
      <email>stefan.bittner@unimedizin-mainz.de</email>
    </contact>
    <contact_backup>
      <last_name>Felix Lüssi, PD Dr.</last_name>
      <phone>+49 6131 17</phone>
      <phone_ext>5278</phone_ext>
      <email>felix.luessi@unimedizin-mainz.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster Klinik für Neurologie</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nico Melzer, PD Dr.</last_name>
      <phone>+49 251 8348</phone>
      <phone_ext>188</phone_ext>
      <email>nico.melzer@ukm.de</email>
    </contact>
    <contact_backup>
      <last_name>Sven Meuth, Prof.</last_name>
      <phone>+49 251 8346</phone>
      <phone_ext>187</phone_ext>
      <email>sven.meuth@ukm.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm, Klinik für Neurologie Neurologische Ambulanz</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Lewerenz, PD Dr.</last_name>
      <phone>+49 731 500</phone>
      <phone_ext>63146</phone_ext>
      <email>jan.lewerenz@uni-ulm.de</email>
    </contact>
    <contact_backup>
      <last_name>Mabule Senel, Dr.</last_name>
      <phone>+49 731 077</phone>
      <phone_ext>5265</phone_ext>
      <email>makbule.senel@uni-ulm.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 12, 2019</study_first_submitted>
  <study_first_submitted_qc>June 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2019</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jena University Hospital</investigator_affiliation>
    <investigator_full_name>Christian Geis</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>autoimmune disease</keyword>
  <keyword>autoimmune encephalitis</keyword>
  <keyword>bortezomib</keyword>
  <keyword>NMDAR</keyword>
  <keyword>LGI1</keyword>
  <keyword>encephalitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Hashimoto Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>It is not yet decided in which way and which data exactly will be shared with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

